PT2411408E - Anticorpos solúveis apenas de cadeia pesada - Google Patents

Anticorpos solúveis apenas de cadeia pesada Download PDF

Info

Publication number
PT2411408E
PT2411408E PT107110694T PT10711069T PT2411408E PT 2411408 E PT2411408 E PT 2411408E PT 107110694 T PT107110694 T PT 107110694T PT 10711069 T PT10711069 T PT 10711069T PT 2411408 E PT2411408 E PT 2411408E
Authority
PT
Portugal
Prior art keywords
antibodies
soluble
heavy
chain
Prior art date
Application number
PT107110694T
Other languages
English (en)
Inventor
Gerardus Grosveld Franklin
Wilhelm Janssens Richard
Drabek Dubravka
Chen Tao
De Boer Ernie
Kingdon Craig Roger
Original Assignee
Kingdon Craig R
Univ Erasmus Med Ct Rotterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40640054&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2411408(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kingdon Craig R, Univ Erasmus Med Ct Rotterdam filed Critical Kingdon Craig R
Publication of PT2411408E publication Critical patent/PT2411408E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Environmental Sciences (AREA)
  • Oncology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT107110694T 2009-03-24 2010-03-19 Anticorpos solúveis apenas de cadeia pesada PT2411408E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0905023.8A GB0905023D0 (en) 2009-03-24 2009-03-24 Binding molecules

Publications (1)

Publication Number Publication Date
PT2411408E true PT2411408E (pt) 2016-03-03

Family

ID=40640054

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107110694T PT2411408E (pt) 2009-03-24 2010-03-19 Anticorpos solúveis apenas de cadeia pesada

Country Status (24)

Country Link
US (2) US8883150B2 (pt)
EP (1) EP2411408B2 (pt)
JP (1) JP5836927B2 (pt)
KR (1) KR20120068757A (pt)
CN (1) CN102482342B (pt)
BR (1) BRPI1012694A2 (pt)
CA (1) CA2756171C (pt)
CY (1) CY1117203T1 (pt)
DK (1) DK2411408T4 (pt)
ES (1) ES2563321T5 (pt)
FI (1) FI2411408T4 (pt)
GB (1) GB0905023D0 (pt)
HR (1) HRP20160158T4 (pt)
HU (1) HUE026473T2 (pt)
MX (1) MX2011010027A (pt)
PL (1) PL2411408T5 (pt)
PT (1) PT2411408E (pt)
RU (1) RU2528737C2 (pt)
SG (1) SG174510A1 (pt)
SI (1) SI2411408T2 (pt)
SM (1) SMT201600044B (pt)
TW (1) TW201040264A (pt)
WO (1) WO2010109165A2 (pt)
ZA (1) ZA201106983B (pt)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1978032A3 (en) 2004-07-22 2009-02-18 Erasmus University Medical Center Rotterdam Binding molecules
SG169348A1 (en) * 2006-01-25 2011-03-30 Univ Erasmus Medical Ct Generation of heavy-chain only antibodies in transgenic animals
DK2346994T3 (da) * 2008-09-30 2022-02-28 Ablexis Llc Knock-in-mus til fremstilling af kimære antistoffer
CN102292445A (zh) 2008-12-18 2011-12-21 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
EP2421357B1 (en) 2009-07-08 2013-01-23 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
PL2954779T3 (pl) 2009-12-10 2019-07-31 Regeneron Pharmaceuticals, Inc. Myszy wytwarzające przeciwciała ciężkołańcuchowe
AU2011234988B2 (en) 2010-03-31 2014-10-30 Ablexis, Llc Genetic engineering of non-human animals for the production of chimeric antibodies
EP2947151A1 (en) * 2010-08-02 2015-11-25 Regeneron Pharmaceuticals, Inc. Binding proteins comprising vl domains
EP2670778A1 (en) * 2011-02-02 2013-12-11 Glaxo Group Limited Novel antigen binding proteins
DE14176593T1 (de) 2011-02-25 2015-03-05 Regeneron Pharmaceuticals, Inc. ADAM6 Mäuse
SI2739740T1 (sl) 2011-08-05 2019-12-31 Regeneron Pharmaceuticals, Inc. Humanizirane univerzalne lahkoverižne miši
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
AU2012311286B2 (en) * 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
SI2627773T1 (sl) 2011-10-17 2017-12-29 Regeneron Pharmaceuticals, Inc., Omejena težka veriga imunoglobulinov pri miših
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
EP2793567B1 (en) 2011-12-20 2019-02-27 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
JP2015512635A (ja) 2012-03-28 2015-04-30 カイマブ・リミテッド クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
NZ717848A (en) * 2012-06-12 2019-03-29 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
CN104994730B (zh) 2013-02-20 2018-12-28 瑞泽恩制药公司 具有修饰的免疫球蛋白重链序列的非人类动物
US9980470B2 (en) 2013-03-14 2018-05-29 Erasmus University Medical Center Antibody production
GB2584364A (en) 2013-03-15 2020-12-02 Abvitro Llc Single cell bar-coding for antibody discovery
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
TW201546284A (zh) 2013-10-01 2015-12-16 Kymab Ltd 動物模式及治療分子
EP3119398A1 (en) * 2014-03-20 2017-01-25 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical formulation comprising a substitued phenyl- (1, 3-dihydro-isoindol-2-yl) -methanone
WO2015143414A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
ES2762640T3 (es) 2014-03-21 2020-05-25 Regeneron Pharma Proteínas VL de unión a antígeno que exhiben diferentes características de unión
KR102541849B1 (ko) 2014-09-15 2023-06-09 에이비비트로, 엘엘씨 고-처리량 뉴클레오티드 라이브러리 서열결정
WO2016062988A1 (en) * 2014-10-22 2016-04-28 Crescendo Biologics Limited Vh scaffold
US20170306039A1 (en) * 2014-10-22 2017-10-26 Crescendo Biologics Limited Human vh domain scaffolds
CN104710528B (zh) * 2015-03-13 2019-02-15 西北农林科技大学 一种特异性结合PRRS病毒非结构蛋白Nsp9纳米抗体及其应用
AU2016232715A1 (en) 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
WO2016150845A1 (en) * 2015-03-20 2016-09-29 Ablynx Nv Glycosylated immunoglobulin single variable domains
EP4335918A3 (en) * 2015-04-03 2024-04-17 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
RU2749674C2 (ru) 2015-07-29 2021-06-16 Аллерган, Инк. Антитела против ang-2, содержащие только тяжелую цепь
JP2018523673A (ja) 2015-08-14 2018-08-23 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Ｐｄｇｆに対する重鎖のみ抗体
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
CN105777894A (zh) * 2016-03-12 2016-07-20 长春力太生物技术有限公司 通过转基因啮齿类动物制备人源化驼类单域抗体的方法
BR112018070353A2 (pt) 2016-04-04 2019-01-29 Eth Zuerich linhagem de célula de mamífero para produção de proteína e geração de biblioteca
WO2017223111A1 (en) 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
RU2021137547A (ru) * 2016-08-24 2022-01-11 Тенеобио, Инк. Трансгенные животные, отличные от человека, продуцирующие модифицированные антитела, содержащие только тяжелые цепи
IL290517B1 (en) 2016-09-14 2024-08-01 Teneobio Inc CD3 binding antibodies
EP3526253A1 (en) * 2016-10-14 2019-08-21 Institut Curie New anti-lsp1 antibody
WO2018144097A1 (en) 2016-11-04 2018-08-09 Akeagen Llc Genetically modified non-human animals and methods for producing heavy chain-only antibodies
KR20230052309A (ko) 2016-12-21 2023-04-19 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
US11267904B2 (en) * 2016-12-28 2022-03-08 Sysmex Corporation Method for controlling affinity of antibody for antigen, antibody whose affinity for antigen has been altered, and its production method
SG11201906540WA (en) 2017-01-19 2019-08-27 Open Monoclonal Tech Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
JP7303126B2 (ja) * 2017-06-20 2023-07-04 テネオバイオ， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
AU2018331421A1 (en) 2017-09-13 2020-04-30 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
AU2018391831B2 (en) * 2017-12-20 2022-08-04 Harbour Biomed (Shanghai) Co., Ltd Antibodies binding CTLA-4 and uses thereof
US11873336B2 (en) 2017-12-22 2024-01-16 Teneobio, Inc. Heavy chain antibodies binding to CD22
WO2019129221A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
AU2019237926A1 (en) * 2018-03-21 2020-09-24 Crystal Bioscience Inc. Transgenic chicken that produces human antibodies
AU2019241350A1 (en) 2018-03-30 2020-07-30 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
WO2019241002A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Transgenic chicken that makes antibodies with long cdr-h3s stabilized by multiple disulfide bridges and diversified by gene conversion
KR20210021024A (ko) * 2018-06-13 2021-02-24 크리스탈 바이오사이언스 주식회사 유전자 변환에 의한 자율 중쇄 가변 도메인의 수정에 의한 항체 생산
SG11202011597RA (en) 2018-07-20 2020-12-30 Teneobio Inc Heavy chain antibodies binding to cd19
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
MX2021004732A (es) 2018-10-26 2021-06-04 Teneobio Inc Anticuerpos de cadena pesada que se unen a cd38.
EP3927432A2 (en) 2019-02-20 2021-12-29 Harbour Antibodies BV Antibodies
CR20210500A (es) 2019-04-05 2021-11-05 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
MA56120A (fr) 2019-06-07 2022-04-13 Amgen Inc Constructions de liaison bispécifiques
CA3140816A1 (en) 2019-06-14 2020-12-17 Nathan Trinklein Multispecific heavy chain antibodies binding to cd22 and cd3
WO2021127489A1 (en) 2019-12-18 2021-06-24 Teneobio, Inc. Heavy chain antibodies binding to cd38
GB202003632D0 (en) 2020-03-12 2020-04-29 Harbour Antibodies Bv SARS-Cov-2 (SARS2, COVID-19) antibodies
EP4121172A1 (en) 2020-04-29 2023-01-25 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
WO2021222578A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
EP4161969A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Bispecific binding constructs
TWI806088B (zh) 2020-06-30 2023-06-21 大陸商和鉑醫藥（上海）有限責任公司 具有H2L2與HCAb結構的結合蛋白
KR20230038211A (ko) 2020-06-30 2023-03-17 테네오바이오, 인코포레이티드 Bcma에 결합하는 다중특이적 항체
IL299232A (en) 2020-06-30 2023-02-01 Harbour Biomed Us Inc Bispecific antibody and its use
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
GB202017555D0 (en) 2020-11-06 2020-12-23 Harbour Antibodies Bv Antibody-conjugated nanoparticles
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
CN116783217A (zh) 2020-12-03 2023-09-19 安进公司 具有多个结合结构域的免疫球蛋白构建体
CN113164621B (zh) 2020-12-08 2022-02-18 和铂医药(上海)有限责任公司 蛋白-药物偶联物和定点偶联方法
EP4258865A1 (en) 2020-12-09 2023-10-18 Trianni, Inc. Heavy chain-only antibodies
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
AU2022226277A1 (en) 2021-02-25 2023-08-31 Teneobio, Inc. Anti-psma antibodies and car-t structures
WO2022183101A1 (en) 2021-02-26 2022-09-01 Teneobio, Inc. Anti-muc1-c antibodies and car-t structures
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
EP4320158A1 (en) 2021-04-06 2024-02-14 Teneobio, Inc. Anti-cd19 antibodies and car-t structures
EP4323403A1 (en) 2021-04-16 2024-02-21 Teneobio, Inc. Anti-cd20 antibodies and car-t structures
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen
GB202112935D0 (en) 2021-09-10 2021-10-27 Harbour Antibodies Bv Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
WO2023036982A1 (en) 2021-09-10 2023-03-16 Harbour Antibodies Bv Anti-sars2-s antibodies
WO2023246578A1 (zh) * 2022-06-24 2023-12-28 成都科伦精准生物科技有限公司 特异性结合gpc3的嵌合抗原受体及其应用
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3333941A1 (de) 1983-09-20 1985-04-04 Karl Kässbohrer Fahrzeugwerke GmbH, 7900 Ulm Fraese
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
ES2338791T3 (es) 1992-08-21 2010-05-12 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
CN1203178C (zh) 1997-10-27 2005-05-25 尤尼利弗公司 多价抗原结合蛋白
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030022240A1 (en) * 2001-04-17 2003-01-30 Peizhi Luo Generation and affinity maturation of antibody library in silico
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US7247301B2 (en) * 2001-06-13 2007-07-24 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
WO2004076677A2 (en) * 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP1978032A3 (en) 2004-07-22 2009-02-18 Erasmus University Medical Center Rotterdam Binding molecules
EP1844073A1 (en) * 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP3415535B1 (en) * 2005-05-20 2020-12-09 Ablynx N.V. Improved nanobodies tm for the treatment of aggregation-mediated disorders
DE202005011297U1 (de) 2005-07-18 2005-11-03 Trw Automotive Electronics & Components Gmbh & Co. Kg Fahrzeug-Haltegriff
SG169348A1 (en) 2006-01-25 2011-03-30 Univ Erasmus Medical Ct Generation of heavy-chain only antibodies in transgenic animals
GB0618345D0 (en) 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US7731969B1 (en) * 2006-12-06 2010-06-08 Neoclone Biotechnology International, Llc Methods for developing and producing antigen-specific antibody-producing cells
CA2688834C (en) * 2007-06-01 2020-01-07 Ronald Buelow Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
MX2010002044A (es) 2007-09-07 2010-03-18 Symphogen As Metodos para produccion recombinante de anticuerpos anti-virus sincitial respiratorio (anti-rsv).
PL2954779T3 (pl) 2009-12-10 2019-07-31 Regeneron Pharmaceuticals, Inc. Myszy wytwarzające przeciwciała ciężkołańcuchowe
DE14176593T1 (de) 2011-02-25 2015-03-05 Regeneron Pharmaceuticals, Inc. ADAM6 Mäuse
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
US10250205B2 (en) 2015-06-22 2019-04-02 Hitachi Kokusai Electric Inc. Power amplifying device

Also Published As

Publication number Publication date
SI2411408T1 (sl) 2016-03-31
SMT201600044B (it) 2016-02-25
MX2011010027A (es) 2011-12-14
RU2011142759A (ru) 2013-04-27
PL2411408T3 (pl) 2016-05-31
US20130323235A1 (en) 2013-12-05
US9365655B2 (en) 2016-06-14
SI2411408T2 (sl) 2023-06-30
TW201040264A (en) 2010-11-16
CY1117203T1 (el) 2017-04-05
EP2411408A2 (en) 2012-02-01
CA2756171C (en) 2020-04-28
ES2563321T3 (es) 2016-03-14
KR20120068757A (ko) 2012-06-27
FI2411408T4 (fi) 2023-05-08
US8883150B2 (en) 2014-11-11
HUE026473T2 (en) 2016-06-28
HRP20160158T4 (hr) 2023-04-28
RU2528737C2 (ru) 2014-09-20
CA2756171A1 (en) 2010-09-30
SG174510A1 (en) 2011-10-28
CN102482342B (zh) 2014-11-12
DK2411408T3 (en) 2016-01-11
PL2411408T5 (pl) 2023-07-10
BRPI1012694A2 (pt) 2018-01-16
AU2010227291A1 (en) 2011-10-27
DK2411408T4 (da) 2023-04-24
WO2010109165A2 (en) 2010-09-30
WO2010109165A3 (en) 2011-02-24
EP2411408B2 (en) 2023-03-22
AU2010227291A8 (en) 2011-11-17
HRP20160158T1 (hr) 2016-03-11
JP2012521211A (ja) 2012-09-13
EP2411408B1 (en) 2015-11-25
US20120151610A1 (en) 2012-06-14
ZA201106983B (en) 2014-12-23
WO2010109165A8 (en) 2011-10-20
GB0905023D0 (en) 2009-05-06
JP5836927B2 (ja) 2015-12-24
CN102482342A (zh) 2012-05-30
ES2563321T5 (es) 2023-06-26

Similar Documents

Publication Publication Date Title
ZA201106983B (en) Soluble "heavy-chain only" antibodies
IL214996A0 (en) Anti-bcma antibodies
IL218724A0 (en) Endoglin antibodies
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
GB0708002D0 (en) Antibodies
LT3023438T (lt) Anti-gitr antikūnai
ZA201107486B (en) Anti-tnf-x antibodies and their uses
EP2494062A4 (en) ANTI-GLP-1R ANTIBODIES AND THEIR USES
ZA201104545B (en) Anti-siglec-15 antibody
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
GB0821100D0 (en) Antibodies
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
GB0718737D0 (en) Antibodies
ZA201006099B (en) Anti-tyrp1 antibodies
GB0920324D0 (en) Antibodies
HK1170745A1 (en) Antibodies against il-17br il-17br
ZA201007976B (en) Anti-pirb antibodies
EP2400984A4 (en) HER2 ANTIBODY COMPOSITIONS
GB0818356D0 (en) Antibodies
GB2473934B (en) Anti-VEEV antibody
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
EP2424892A4 (en) DC-STAMP ANTIBODY
GB0908945D0 (en) Antibodies
GB0724185D0 (en) Antibodies